To lead the development, commercialization and delivery of cell therapies, gene therapies and other advanced therapies for SA, Africa, through collaborations with patient communities, clinicians, researchers, industry, organized labour and government in an advanced therapies ecosystem.

Future cells

Donor Selection for Aphersis

Platelet Biology

Mesenchymal Stromal Cells (MSC) Fresh or Fit

Mesenchymal Stromal Cells are cells isolated from bone marrow, adipose, and other tissue sources, with multipotent differentiation capacity in vitro.

Clinical Apheresis - Overview, ASFA 2019 Guidelines & Update on Clinical Trials for Plasma Exchange in Severe COVID 19 Patients” Dr Poole, Dr Mickael Beraud & Dr Hassanein

Clinical Apheresis

Clinical Apheresis offeres services to a wide range of patients and support the three largest specialist`s groups` professional society meetings and have presented to:

Donor Lymphocyte Infusions by Dr Tanya Glatt

Cellular Therapy Laboratory

Clinical apheresis is the application of apheresis medicine to patients in hospital settings with a wide variety of indications. The most common indications for clinical apheresis is in the medical disciplines of hematology, oncology, neurology, nephrology and intensive care medicine.

  1. start with the webinar - cellular therapies
  2. (then the neurology link)
  3. Remove fresh acute HIV study manuscript

For more information : https://sanbs.org.za/specialised-services/


Future Cells: SANBS’s role in advanced therapeutic health products

In this presentation, we answer five questions: 

1. Why do we need to consider "future cells"?
2. What is SANB's role in "future cells"?
3. Where are we in the process of implementing the plan?
4. What are some of the current advanced therapies being applied to diseases in clinical trial situations? 
5. "Future cells" approved for use of patients.